Literature DB >> 11558866

A systematic review of the associations between dose regimens and medication compliance.

A J Claxton1, J Cramer, C Pierce.   

Abstract

BACKGROUND: Previous reviews of the literature on medication compliance have confirmed the inverse relationship between number of daily doses and rate of compliance. However, compliance in most of these studies was based on patient self-report, blood-level monitoring, prescription refills, or pill count data, none of which are as accurate as electronic monitoring (EM).
OBJECTIVE: In this paper, we review studies in which compliance was measured with an EM device to determine the associations between dose frequency and medication compliance.
METHODS: Articles included in this review were identified through literature searches of MEDLINE, PsychInfo, HealthStar, Health & Psychosocial Instruments, and the Cochrane Library using the search terms patient compliance, patient adherence, electronic monitoring, and MEMS (medication event monitoring systems). The review was limited to studies reporting compliance measured by EM devices, the most accurate compliance assessment method to date. Because EM was introduced only in 1986, the literature search was restricted to the years 1986 to 2000. In the identified studies, data were pooled to calculate mean compliance with once-daily, twice-daily, 3-times-daily, and 4-times-daily dosing regimens. Because of heterogeneity in definitions of compliance, 2 major categories of compliance rates were defined: dose-taking (taking the prescribed number of pills each day) and dose-timing (taking pills within the prescribed time frame).
RESULTS: A total of 76 studies were identified. Mean dose-taking compliance was 71% +/- 17% (range, 34%-97%) and declined as the number of daily doses increased: 1 dose = 79% +/- 14%, 2 doses = 69% +/- 15%, 3 doses = 65% +/- 16%, 4 doses = 51% +/- 20% (P < 0.001 among dose schedules). Compliance was significantly higher for once-daily versus 3-times-daily (P = 0.008), once-daily versus 4-times-daily (P < 0.001), and twice-daily versus 4-times-daily regimens (P = 0.001); however, there were no significant differences in compliance between once-daily and twice-daily regimens or between twice-daily and 3-times-daily regimens. In the subset of 14 studies that reported dose-timing results, mean dose-timing compliance was 59% +/- 24%; more frequent dosing was associated with lower compliance rates.
CONCLUSIONS: A review of studies that measured compliance using EM confirmed that the prescribed number of doses per day is inversely related to compliance. Simpler, less frequent dosing regimens resulted in better compliance across a variety of therapeutic classes.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11558866     DOI: 10.1016/s0149-2918(01)80109-0

Source DB:  PubMed          Journal:  Clin Ther        ISSN: 0149-2918            Impact factor:   3.393


  620 in total

Review 1.  Accounting for noncompliance in pharmacoeconomic evaluations.

Authors:  D A Hughes; A Bagust; A Haycox; T Walley
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

Review 2.  Association between medication regimen complexity and pharmacotherapy adherence: a systematic review.

Authors:  Laís Lessa Pantuzza; Maria das Graças Braga Ceccato; Micheline Rosa Silveira; Luane Mendes Ribeiro Junqueira; Adriano Max Moreira Reis
Journal:  Eur J Clin Pharmacol       Date:  2017-08-04       Impact factor: 2.953

Review 3.  Stavudine once daily.

Authors:  Susan M Cheer; Karen L Goa
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 4.  Under-prescribing and non-adherence to medications after coronary bypass surgery in older adults: strategies to improve adherence.

Authors:  David Sengstock; Peter Vaitkevicius; Ahmed Salama; Robert M Mentzer
Journal:  Drugs Aging       Date:  2012-02-01       Impact factor: 3.923

5.  Objective assessment of nonadherence and unknown co-medication in hospitalized patients.

Authors:  Florentine Carow; Karin Rieger; Ingeborg Walter-Sack; Markus R Meyer; Frank T Peters; Hans H Maurer; Walter E Haefeli
Journal:  Eur J Clin Pharmacol       Date:  2012-02-22       Impact factor: 2.953

6.  Perspective on dabigatran etexilate dosing: why not follow standard pharmacological principles?

Authors:  Paul K L Chin; Jane W A Vella-Brincat; Murray L Barclay; Evan J Begg
Journal:  Br J Clin Pharmacol       Date:  2012-11       Impact factor: 4.335

7.  Transdermal patches for the treatment of neurologic conditions in elderly patients: a review.

Authors:  Martin R Farlow; Monique Somogyi
Journal:  Prim Care Companion CNS Disord       Date:  2011

8.  Helping our patients to adhere to chronic medications: a new arrow for the quiver.

Authors:  William H Shrank
Journal:  J Gen Intern Med       Date:  2011-12       Impact factor: 5.128

9.  Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women.

Authors:  V Rabenda; R Mertens; V Fabri; J Vanoverloop; F Sumkay; C Vannecke; A Deswaef; G A Verpooten; J Y Reginster
Journal:  Osteoporos Int       Date:  2008-06       Impact factor: 4.507

10.  Medication-taking among adult renal transplant recipients: barriers and strategies.

Authors:  Elisa J Gordon; Mary Gallant; Ashwini R Sehgal; David Conti; Laura A Siminoff
Journal:  Transpl Int       Date:  2009-01-16       Impact factor: 3.782

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.